Dyskeratosis Congenita: Background, Pathophysiology, Etiology (original) (raw)

Background

Dyskeratosis congenita (DKC), also known as Zinsser-Engman-Cole syndrome, was first described in 1906. It is a rare, progressive bone marrow failure syndrome characterized by the triad of reticulated skin hyperpigmentation, nail dystrophy, and oral leukoplakia. Evidence exists for telomerase dysfunction, ribosome deficiency, and protein synthesis dysfunction in this disorder. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. [1, 2]

eMedicine Logo

Pathophysiology

To date, there are 14 genes that have been identified with dyskeratosis congenita (DKC): ACD, DCK1, TERC, TERT, NOP10, NHP2, TINF2, USB1, TCAB1, CTC1, PARN, RTEL1, WRAP53, and C16orf57. [3, 4, 5, 6] DKC is genetically heterogeneous, with X-linked recessive (Mendelian Inheritance in Man [MIM] 305000), autosomal dominant (MIM 127550), and autosomal recessive (MIM 224230) subtypes based on different patterns of inheritance. DKC is related to telomerase dysfunction [7, 8] ; all genes associated with this syndrome (ie, DKC1, TERT, TERC, NOP10) encode proteins in the telomerase complex responsible for maintaining telomeres at the ends of chromosomes regarding shortening length, protection, and replication. [9]

In the X-linked recessive form, the gene defect lies in the DKC1 gene (located at Xq28), which encodes for the protein dyskerin. Dyskerin is composed of 514 amino acids and has a role in ribosomal RNA processing and telomere maintenance. [10, 11, 12, 13] Modification of dyskerin by SUMOylation has been shown to stabilize the protein. In addition, a mutation in the DKC1 gene is also found on exon 15, revealing a duplication, which adds a lysine residue on a polylysine tract on the C-terminus. All in all, there have been over 50 mutations found in DKC1. [14, 15, 16, 17] One study found that mutations in SHQ1 (a dyskerin chaperone) affect dyskerin function. [18] Loss of DKC1 has been reported to induce oxidative stress independent of telomere shortening. [13]

In the autosomal dominant form, mutations in the RNA component of telomerase (TERC) or telomerase reverse transcriptase (TERT) are responsible for disease phenotype. [8, 19, 20] One study reported an RNA-binding protein, human antigen R (HuR), that facilitates TERC methylation and promotes TERT/TERC complex assembly. [21] Mutations in either HuR or TERC can weaken the HuR-TERC binding and reduce TERC methylation, resulting in decreased telomerase activity. [21]

Another gene implicated in DKC, TINF2, encodes a key component of the protein shelterin, which plays a role in telomere homeostasis. [13] Mutations in TINF2 could lead to DKC or Revesz syndrome, a rare variant of DKC. [6] Both an autosomal dominant inheritance pattern and de novo occurrence have been associated with TINF2 mutations. [13, 22] In cases of DKC caused by TINF2 mutations, basal ganglia calcification and pulmonary fibrosis have been reported. [22, 23] Revesz syndrome mainly manifests as bilateral exudative retinopathy (including hemorrhages and other vascular irregularities), intrauterine growth restriction, intracranial calcifications, and neurocognitive defects. [6, 24, 25]

Defects in the NOP10 gene were found in association with autosomal recessive DKC. [26] NOP10 encodes small nucleolar ribonucleoproteins (snoRNP) associated with the telomerase complex. In persons with autosomal dominant DKC and in terc-/- knockout mice, genetic anticipation (ie, increasing severity and/or earlier disease presentation with each successive generation) has been reported. [13, 27] Another case report found a novel, homozygous WRAP53 (antisense to TP53) Arg298Trp mutation underlying DKC. [28]

A heterozygous mutation was found on the conserved telomere maintenance component 1 gene (CTC1). This implication is also associated with a pleiotropic syndrome, Coats plus. [29, 30]

Homozygous autosomal recessive mutations in RTEL1 lead to similar phenotypes that parallel with Hoyeraal-Hreidarsson (HH) syndrome, a severe variant of DKC characterized by cerebellar hypoplasia, bone marrow failure, intrauterine growth restriction and immunodeficiency. [6] It is associated with short, heterogeneous telomeres. In the presence of functional DNA replication, RTEL1 mutations produce a large amount of extrachromosomal T-circles. Enzymes remove the T-circles and therefore shorten the telomere. RTEL1 has a role in managing DNA damage by increasing sensitivity; therefore, mutations on this gene cause both telomeric and nontelomeric causes of DKC. [31, 32, 33, 34]

Patients with DKC have reduced telomerase activity and abnormally short tracts of telomeric DNA compared with normal controls. [35, 36] Telomeres are repeat structures found at the ends of chromosomes that function to stabilize chromosomes. With each round of cell division, the length of telomeres is shortened and the enzyme telomerase compensates by maintaining telomere length in germline and stem cells. Because telomeres function to maintain chromosomal stability, telomerase has a critical role in preventing cellular senescence and cancer progression. Rapidly proliferating tissues with the greatest need for telomere maintenance (eg, bone marrow) are at greatest risk for failure. DKC1 has been found to be a direct target of the c-myc oncogene, strengthening the connection between DKC and malignancy. [37]

Analysis of 270 families in the DKC registry found that mutations in dyskerin (DKC1), TERT, and TERC only account for 64% of patients, with an additional 1% due to NOP10, suggesting that other genes associated with this syndrome are, as yet, unidentified. In addition to the mutations that directly affect telomere length, studies also indicate that a DKC diagnosis should not be based solely on the length of the telomere, but also the fact that there are defects in telomere replication and protection. [9] In addition, revertant mosaicism has been a new recurrent event in DKC. [38]

Studies have also shown the significance of DNA methylation. A study in patients with DKC has shown changes in the CpG sites affiliated with the internal promoter region of the PR domain, specifically containing 8 (PRDM8) when compared with healthy control groups. [21, 39]

eMedicine Logo

Etiology

Mutations in DKC1 have been shown to cause the X-linked form of dyskeratosis congenita (DKC). Specifically, the presence of a missense mutation on DKC1 in females has been shown to compromise telomerase RNA levels, putting them at increased risk for penetrant telomere phenotypes that may be associated with increased clinical morbidity. [40]

The inheritance pattern of most cases of DKC is X-linked recessive, but autosomal dominant and recessive patterns have been reported. Autosomal dominant DKC is associated with TERC, TERT, and TINF2 mutations in some cases, and NOP10, TERT, NHP2, and RTEL1 mutations have been associated with some cases of autosomal recessive DKC. Fifty percent of DKC patients with the clinical phenotypes have a mutation in their genes. [14]

eMedicine Logo

Epidemiology

Frequency

Dyskeratosis congenita (DKC) is estimated to occur in 1 in 1 million people. More than 200 individuals have been reported in the literature.

Race

No racial predilection has been reported. The DKC registry includes patients from all over the world, with families from at least 40 different countries currently in the registry.

Sex

The male-to-female ratio is approximately 3:1.

Age

Patients usually present during the first decade of life, with the skin hyperpigmentation and nail changes typically appearing first.

eMedicine Logo

Prognosis

Dyskeratosis congenita (DKC) is a multisystem disorder that carries a poor prognosis (mean survival of 30 y), with most deaths related to infections, bleeding, and malignancy. In the DKC registry, approximately 70% of affected individuals died of bone marrow failure or its complications, and these deaths occurred at a median age of 16 years. Therapeutic interventions are mostly palliative, but BMT and SCT for aplastic anemia have been tried with variable success. Wide variation in clinical phenotype may occur in individuals, suggesting that other genetic or environmental factors may be contributory. The prognosis is worse for the X-linked and autosomal forms compared with the autosomal dominant form.

Hoyeraal-Hreidarsson (HH) syndrome is also associated with mutations in DKC1. [41] Mutations in this gene have been described in patients with HH syndrome, which is characterized by intrauterine growth restriction, microcephaly, intellectual disability, cerebellar malformation, immunodeficiency, and progressive bone marrow failure. [41] Mucosal ulcerations have been found in a few patients. Some authorities hypothesize that HH syndrome may be a severe variant of DKC in which affected individuals die before the development of mucocutaneous findings. [41] Patients with HH syndrome have significantly shorter telomeres than those with the milder form of disease. [41]

In addition, studies have also found that not only are shortened telomeres associated with HH syndrome, but more so are telomere dysfunction and telomere protection. [16] The severe neurologic deficits in this severe form point to an important role of the DKC1 gene in brain function.

The biology of telomere shortening is not only associated with DKC, but it has comorbid associations with neuropsychiatric conditions. A cohort study with 6 pediatric and 8 adult subjects showed that 83% of the children and 88% of the adult had a comorbid neuropsychiatric condition. These conditions include schizophrenia, anxiety, intellectual disability, attention-deficit/hyperactivity disorder, adjustment disorder, mood disorders, or pervasive developmental disorders. [42]

Mortality/morbidity

In an analysis of individuals with DKC, approximately 70% of patients died either directly from bone marrow failure or from its complications at a median age of 16 years. Eleven percent died from sudden pulmonary complications; a further 11% died of pulmonary disease in the bone marrow transplantation (BMT) setting. Seven percent died from malignancy (eg, Hodgkin disease, pancreatic carcinoma). Fatal opportunistic infections such as Pneumocystis carinii pneumonia and cytomegalovirus infection have been reported.

eMedicine Logo

  1. Jyonouchi S, Forbes L, Ruchelli E, Sullivan KE. Dyskeratosis congenita: a combined immunodeficiency with broad clinical spectrum--a single-center pediatric experience. Pediatr Allergy Immunol. 2011 May. 22(3):313-9. [QxMD MEDLINE Link].
  2. Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013 Jun. 6(3):327-37. [QxMD MEDLINE Link].
  3. Islam A, Rafiq S, Kirwan M, et al. Haematological recovery in dyskeratosis congenita patients treated with danazol. Br J Haematol. 2013 Sep. 162(6):854-6. [QxMD MEDLINE Link].
  4. Pagon RA, Adam MP, Ardinger HH, eds. GeneReviews. Seattle, Wash: University of Washington; 1993-2016.
  5. Kilic SS, Cekic S. Juvenile Idiopathic Inflammatory Myopathy in a Patient With Dyskeratosis Congenita Due to C16orf57 Mutation. J Pediatr Hematol Oncol. 2016 Mar. 38 (2):e75-7. [QxMD MEDLINE Link].
  6. Zhang J, Li M, Yao Z. Updated review of genetic reticulate pigmentary disorders. Br J Dermatol. 2017 Oct. 177 (4):945-959. [QxMD MEDLINE Link].
  7. Bessler M, Du HY, Gu B, Mason PJ. Dysfunctional telomeres and dyskeratosis congenita. Haematologica. 2007 Aug. 92(8):1009-12. [QxMD MEDLINE Link].
  8. Garcia CK, Wright WE, Shay JW. Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res. 2007. 35(22):7406-16. [QxMD MEDLINE Link].
  9. Touzot F, Le Guen T, de Villartay JP, Revy P. Dyskeratosis congenita: short telomeres are not the rule. Science of Medicine. June 2012. 28(6-7):618-24.
  10. Mason PJ, Wilson DB, Bessler M. Dyskeratosis congenita -- a disease of dysfunctional telomere maintenance. Curr Mol Med. 2005 Mar. 5(2):159-70. [QxMD MEDLINE Link].
  11. Walne AJ, Marrone A, Dokal I. Dyskeratosis congenita: a disorder of defective telomere maintenance?. Int J Hematol. 2005 Oct. 82(3):184-9. [QxMD MEDLINE Link].
  12. Zeng XL, Thumati NR, Fleisig HB, Hukezalie KR, Savage SA, Giri N, et al. The accumulation and not the specific activity of telomerase ribonucleoprotein determines telomere maintenance deficiency in X-linked dyskeratosis congenita. Hum Mol Genet. 2011 Nov 4. [QxMD MEDLINE Link].
  13. Ibáñez-Cabellos JS, Pérez-Machado G, Seco-Cervera M, Berenguer-Pascual E, García-Giménez JL, Pallardó FV. Acute telomerase components depletion triggers oxidative stress as an early event previous to telomeric shortening. Redox Biol. 2018 Apr. 14:398-408. [QxMD MEDLINE Link].
  14. Allenspach EJ, Bellodi C, Jeong D, et al. Common variable immunodeficiency as the initial presentation of dyskeratosis congenita. J Allergy Clin Immunol. 2013 Jul. 132(1):223-6. [QxMD MEDLINE Link].
  15. Brault ME, Lauzon C, Autexier C. Dyskeratosis congenita mutations in dyskerin SUMOylation consensus sites lead to impaired telomerase RNA accumulation and telomere defects. Hum Mol Genet. 2013 Sep 1. 22(17):3498-507. [QxMD MEDLINE Link].
  16. Touzot F, Gaillard L, Vasquez N, et al. Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita. J Allergy Clin Immunol. 2012 Feb. 129(2):473-82, 482.e1-3. [QxMD MEDLINE Link].
  17. Ratnasamy V, Navaneethakrishnan S, Sirisena ND, Grüning NM, Brandau O, Thirunavukarasu K, et al. Dyskeratosis congenita with a novel genetic variant in the DKC1 gene: a case report. BMC Med Genet. 2018 May 25. 19 (1):85. [QxMD MEDLINE Link].
  18. Bizarro J, Meier UT. Inherited SHQ1 mutations impair interaction with NAP57/dyskerin, a major target in dyskeratosis congenita. Mol Genet Genomic Med. 2017 Nov. 5 (6):805-808. [QxMD MEDLINE Link].
  19. Marrone A, Sokhal P, Walne A, Beswick R, Kirwan M, Killick S, et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica. 2007 Aug. 92(8):1013-20. [QxMD MEDLINE Link].
  20. Marrone A, Walne A, Tamary H, Masunari Y, Kirwan M, Beswick R, et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood. 2007 Dec 15. 110(13):4198-205. [QxMD MEDLINE Link].
  21. Tang H, Wang H, Cheng X, Fan X, Yang F, Zhang M, et al. HuR regulates telomerase activity through TERC methylation. Nat Commun. 2018 Jun 7. 9 (1):2213. [QxMD MEDLINE Link].
  22. Abdollahi M, Gao MM, Munoz DG. Distinct pattern of neostriatal calcifications in dyskeratosis congenita: A case report and literature review. Clin Neuropathol. 2018 Nov/Dec. 37 (6):277-282. [QxMD MEDLINE Link].
  23. Du H, Guo Y, Ma D, Tang K, Cai D, Luo Y, et al. A case report of heterozygous TINF2 gene mutation associated with pulmonary fibrosis in a patient with dyskeratosis congenita. Medicine (Baltimore). 2018 May. 97 (19):e0724. [QxMD MEDLINE Link].
  24. Moussa K, Huang JN, Moore AT. Revesz syndrome masquerading as traumatic retinal detachment. J AAPOS. 2017 Oct. 21 (5):422-425.e1. [QxMD MEDLINE Link].
  25. Gupta MP, Talcott KE, Kim DY, Agarwal S, Mukai S. Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies. Ophthalmic Genet. 2017 Jan-Feb. 38 (1):51-60. [QxMD MEDLINE Link].
  26. Walne AJ, Vulliamy T, Marrone A, Beswick R, Kirwan M, Masunari Y, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet. 2007 Jul 1. 16(13):1619-29. [QxMD MEDLINE Link].
  27. Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao PH. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003 Jan 10. 299(5604):259-62. [QxMD MEDLINE Link].
  28. Shao Y, Feng S, Huang J, Huo J, You Y, Zheng Y. A unique homozygous WRAP53 Arg298Trp mutation underlies dyskeratosis congenita in a Chinese Han family. BMC Med Genet. 2018 Mar 7. 19 (1):40. [QxMD MEDLINE Link].
  29. Keller RB, Gagne KE, Usmani GN, Asdourian GK, Williams DA, Hofmann I, et al. CTC1 Mutations in a patient with dyskeratosis congenita. Pediatr Blood Cancer. 2012 Aug. 59(2):311-4. [QxMD MEDLINE Link]. [Full Text].
  30. Painho T, Conceição C, Kjöllerström P, Batalha S. Retinopathy and bone marrow failure revealing Coats plus syndrome. BMJ Case Rep. 2018 Mar 9. 2018:[QxMD MEDLINE Link].
  31. Ballew BJ, Joseph V, De S, et al. A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome. PLoS Genet. 2013 Aug. 9(8):e1003695. [QxMD MEDLINE Link]. [Full Text].
  32. Kuang FM, Tang LL, Zhang H, Xie M, Yang MH, Yang LC, et al. [Recurrent pulmonary infection and oral mucosal ulcer]. Zhongguo Dang Dai Er Ke Za Zhi. 2017 Apr. 19 (4):452-457. [QxMD MEDLINE Link].
  33. Marsh JCW, Gutierrez-Rodrigues F, Cooper J, Jiang J, Gandhi S, Kajigaya S, et al. Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms. Blood Adv. 2018 Jan 9. 2 (1):36-48. [QxMD MEDLINE Link].
  34. Ungar RA, Giri N, Pao M, Khincha PP, Zhou W, Alter BP, et al. Complex phenotype of dyskeratosis congenita and mood dysregulation with novel homozygous RTEL1 and TPH1 variants. Am J Med Genet A. 2018 Jun. 176 (6):1432-1437. [QxMD MEDLINE Link].
  35. Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 2011 Nov 4. [QxMD MEDLINE Link].
  36. Gadalla SM, Katki HA, Shebl FM, Giri N, Alter BP, Savage SA. The Relationship between DNA Methylation and Telomere Length in Dyskeratosis Congenita. Aging Cell. 2011 Oct 8. [QxMD MEDLINE Link].
  37. Alawi F, Lee MN. DKC1 is a direct and conserved transcriptional target of c-MYC. Biochem Biophys Res Commun. 2007 Nov 3. 362(4):893-8. [QxMD MEDLINE Link].
  38. Jongmans MC, Verwiel ET, Heijdra Y, et al. Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita. Am J Hum Genet. 2012 Mar 9. 90(3):426-33. [QxMD MEDLINE Link]. [Full Text].
  39. Weidner CI, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, et al. DNA methylation in PRDM8 is indicative for dyskeratosis congenita. Oncotarget. 2016 Mar 8. 7 (10):10765-72. [QxMD MEDLINE Link].
  40. Alder JK, Parry EM, Yegnasubramanian S, et al. Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat. 2013 Nov. 34(11):1481-5. [QxMD MEDLINE Link]. [Full Text].
  41. Martínez P, Blasco MA. Telomere-driven diseases and telomere-targeting therapies. J Cell Biol. 2017 Apr 3. 216 (4):875-887. [QxMD MEDLINE Link].
  42. Rackley S, Pao M, Seratti GF, et al. Neuropsychiatric conditions among patients with dyskeratosis congenita: a link with telomere biology?. Psychosomatics. 2012 May-Jun. 53(3):230-5. [QxMD MEDLINE Link]. [Full Text].
  43. Schmitt K, Beier F, Panse J, Brümmendorf TH. [(Pan-)cytopenia as first manifestation of kryptic telomeropathies in adults]. Dtsch Med Wochenschr. 2016 Oct. 141 (21):1578-1580. [QxMD MEDLINE Link].
  44. Vettukattil JJ. Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?. Curr Cardiol Rev. 2017. 13 (3):244-250. [QxMD MEDLINE Link].
  45. Qureishi A, Lamyman A, Silva P, Cox G. Posterior pharyngeal wall squamous cell carcinoma arising in a patient with dyskeratosis congenita. J Laryngol Otol. 2012 Dec. 126(12):1299-301. [QxMD MEDLINE Link].
  46. Gleeson M, O'Marcaigh A, Cotter M, Brosnahan D, Vulliamy T, Smith OP. Retinal vasculopathy in autosomal dominant dyskeratosis congenita due to TINF2 mutation. Br J Haematol. 2012 Dec. 159(5):498. [QxMD MEDLINE Link].
  47. Zheng XY, Xu J, Li W, Li SS, Shi CP, Zhao ZY, et al. Frosted Branch Angiitis in Pediatric Dyskeratosis Congenita: A Case Report. Medicine (Baltimore). 2016 Mar. 95 (12):e3106. [QxMD MEDLINE Link].
  48. Peene G, Smets E, Legius E, Cassiman C. Unilateral Coats'-like disease and an intragenic deletion in the TERC gene: A case report. Ophthalmic Genet. 2018 Apr. 39 (2):247-250. [QxMD MEDLINE Link].
  49. Parchand S, Barwad A. Cytomegalovirus Retinitis as a Presenting Feature of Multisystem Disorder: Dyskeratosis Congenita. Middle East Afr J Ophthalmol. 2017 Oct-Dec. 24 (4):219-221. [QxMD MEDLINE Link].
  50. Olson TS, Chan ES, Paessler ME, et al. Liver failure due to hepatic angiosarcoma in an adolescent with dyskeratosis congenita. J Pediatr Hematol Oncol. 2014 May. 36(4):312-5. [QxMD MEDLINE Link]. [Full Text].
  51. Calado RT, Brudno J, Mehta P, Kovacs JJ, Wu C, Zago MA, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 2011 May. 53(5):1600-7. [QxMD MEDLINE Link]. [Full Text].
  52. Kamel A, Sayari T, Jellouli M, Hammi Y, Louzir RG, Gargah T. Diffuse Mesangial Sclerosis in a Child With Dyskeratosis Congenita Leading to End-stage Renal Disease. Iran J Kidney Dis. 2016 Nov. 10 (6):416-418. [QxMD MEDLINE Link].
  53. Kutbay NO, Yurekli BS, Erdemir Z, Karaca E, Unal I, Yaman B, et al. A case of dyskeratosis congenita associated with hypothyroidism and hypogonadism. Hormones (Athens). 2016 Apr. 15 (2):297-9. [QxMD MEDLINE Link].
  54. Penmatsa C, Jampanapalli SR, Bezawada S, Birapu UK, Radharapu VK. Zinsser-Cole-Engman Syndrome: A Rare Case Report. J Clin Diagn Res. 2016 Jun. 10 (6):ZD07-9. [QxMD MEDLINE Link].
  55. Walne AJ, Collopy L, Cardoso S, Ellison A, Plagnol V, Albayrak C, et al. Marked overlap of four genetic syndromes with dyskeratosis congenita confounds clinical diagnosis. Haematologica. 2016 Oct. 101 (10):1180-1189. [QxMD MEDLINE Link].
  56. Güngör Ş, Erdemir AV, Göncü EK, Gürel MS, Özekinci S. A case of dyskeratosis congenita with dermoscopic and reflectance confocal microscopic features. J Am Acad Dermatol. 2015 Jul. 73 (1):e11-3. [QxMD MEDLINE Link].
  57. Dokal I, Vulliamy T. Dyskeratosis congenita: its link to telomerase and aplastic anaemia. Blood Rev. 2003 Dec. 17(4):217-25. [QxMD MEDLINE Link].
  58. Field JJ, Mason PJ, An P, Kasai Y, McLellan M, Jaeger S. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. J Pediatr Hematol Oncol. 2006 Jul. 28(7):450-3. [QxMD MEDLINE Link].
  59. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007 Sep 1. 110(5):1439-47. [QxMD MEDLINE Link].
  60. Dokal I, Vulliamy T, Mason P, Bessler M. Clinical utility gene card for: dyskeratosis congenita. Eur J Hum Genet. 2011 Nov. 19(11):[QxMD MEDLINE Link]. [Full Text].
  61. Elmahadi S, Muramatsu H, Kojima S. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita. Curr Opin Hematol. 2016 Nov. 23 (6):501-507. [QxMD MEDLINE Link].
  62. Ostronoff F, Ostronoff M, Calixto R, Florêncio R, Domingues MC, Souto Maior AP, et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. Biol Blood Marrow Transplant. 2007 Mar. 13(3):366-8. [QxMD MEDLINE Link].
  63. Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, et al. A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 May. 22 (5):884-8. [QxMD MEDLINE Link].
  64. Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. Biol Blood Marrow Transplant. 2013 Jun 8. [QxMD MEDLINE Link].
  65. Erduran E, Hacisalihoglu S, Ozoran Y. Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin. J Pediatr Hematol Oncol. 2003 Apr. 25(4):333-5. [QxMD MEDLINE Link].
  66. Calado RT, Clé DV. Treatment of inherited bone marrow failure syndromes beyond transplantation. Hematology Am Soc Hematol Educ Program. 2017 Dec 8. 2017 (1):96-101. [QxMD MEDLINE Link].
  67. Giri N, Pitel PA, Green D, Alter BP. Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol. 2007 Sep. 138(6):815-7. [QxMD MEDLINE Link].
  68. Khincha PP, Bertuch AA, Gadalla SM, Giri N, Alter BP, Savage SA. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Adv. 2018 Jun 12. 2 (11):1243-1249. [QxMD MEDLINE Link].
  69. Hartman RI, Hill-Kayser CE. Proton therapy and radiation sensitivity in dyskeratosis congenita. J Pediatr Hematol Oncol. 2014 Jan. 36(1):e51-3. [QxMD MEDLINE Link].
  70. Machado-Pinilla R, Carrillo J, Manguan-Garcia C, et al. Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain. Clin Transl Oncol. 2012 Oct. 14(10):755-63. [QxMD MEDLINE Link]. [Full Text].
  71. Serravallo M, Jagdeo J, Glick SA, Siegel DM, Brody NI. Sirtuins in dermatology: applications for future research and therapeutics. Arch Dermatol Res. 2013 May. 305(4):269-82. [QxMD MEDLINE Link].
  72. Sinha S, Trivedi V, Krishna A, Rao N. Dyskeratosis congenita- management and review of complications: a case report. Oman Med J. 2013 Jul. 28(4):281-4. [QxMD MEDLINE Link]. [Full Text].
  73. Bohn OL, Whitten J, Spitzer B, et al. Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita. Int J Surg Pathol. 2013 Oct. 21(5):520-5. [QxMD MEDLINE Link].
  74. Isoda T, Mitsuiki N, Ohkawa T, et al. Irreversible leukoencephalopathy after reduced-intensity stem cell transplantation in a dyskeratosis congenita patient with TINF2 mutation. J Pediatr Hematol Oncol. 2013 May. 35(4):e178-82. [QxMD MEDLINE Link].
  75. Shankar RK, Giri N, Lodish MB, Sinaii N, Reynolds JC, Savage SA, et al. Bone mineral density in patients with inherited bone marrow failure syndromes. Pediatr Res. 2017 Sep. 82 (3):458-464. [QxMD MEDLINE Link].
  76. Glousker G, Lingner J. When Telomerase Causes Telomere Loss. Dev Cell. 2018 Feb 5. 44 (3):281-283. [QxMD MEDLINE Link].
  77. Bongiorno M, Rivard S, Hammer D, Kentosh J. Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Oct. 124 (4):e239-e242. [QxMD MEDLINE Link].
  78. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017 Nov 23. 130 (21):2257-2264. [QxMD MEDLINE Link].
  79. Thanos A, Todorich B, Hypes SM, Yonekawa Y, Thomas B, Randhawa S, et al. Retinal vascular tortuosity and exudative retinopathy in a family with dyskeratosis congenita masquerading as familial exudative vitreoretinopathy. Retin Cases Brief Rep. 2017 Winter. 11 Suppl 1:S187-S190. [QxMD MEDLINE Link].

Author

David T Robles, MD, PhD, FAAD Dermatologist, Oak Tree Dermatology

David T Robles, MD, PhD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

Arthur Yukuang Chang, MS

Disclosure: Nothing to disclose.

Jacquiline Habashy, DO, MSc Resident Physician, Department of Dermatology, Western University of Health Sciences College of Osteopathic Medicine of the Pacific

Jacquiline Habashy, DO, MSc is a member of the following medical societies: American Osteopathic College of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Van Perry, MD Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas School of Medicine at San Antonio

Van Perry, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Emeritus Professor, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, American Contact Dermatitis Society, Association of Military Dermatologists, Association of Professors of Dermatology, American Dermatological Association, Women's Dermatologic Society, Medical Dermatology Society, Dermatology Foundation, Society for Investigative Dermatology, Washington DC Dermatological Society, Atlantic Dermatologic Society, Philadelphia Dermatological Society, Pennsylvania Academy of Dermatology, College of Physicians of Philadelphia

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier
Served as a speaker for various universities, dermatology societies, and dermatology departments.

Additional Contributors

Jean Paul Ortonne, MD Chair, Department of Dermatology, Professor, Hospital L'Archet, Nice University, France

Jean Paul Ortonne, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Acknowledgements

Jonathan M Olson, MD Fellow, Division of Dermatology, University of Washington Medical Center

Jonathan M Olson, MD is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.